• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

FY 1998 PDUFA Financial Report: Appendix B

Table of Contents

Previous Section: Appendix A: Conditions for Assessment and Use of Fees

EXEMPTIONS AND WAIVERS

Beginning in FY 1993, PDUFA directed FDA to waive or reduce fees in five different circumstances:

  • when a waiver is necessary to protect the public health;
  • when a fee is a significant barrier to innovation;
  • when the fees paid exceed FDA's costs of reviewing a firm's human drug applications;
  • when imposition of the fee creates an inequity between certain 505(b) (1) and 505(b)(2) human drug applications and;
  • when a sponsor withdraws a pending human drug application after FDA has filed it, but before FDA has performed substantial work on the marketing application.

In addition, under FDAMA new exemptions from fees have been added beginning in FY 1998. These specific exemptions are automatic and do not require a waiver request. They include:

  • human drug applications for designated orphan products (designated for rare diseases or conditions affecting fewer than 200,000 patients in the United States);
  • supplemental applications for pediatric indications for use.

Beginning in FY 1998, FDAMA also provides a waiver for certain small businesses for the full application fee for the first application submitted. Before FY 1998, only half of the application fee could be granted a small business exception.

The additional statutory exemptions in FY 1998 resulted in a substantial loss of revenue, as can be seen at the top of the chart on the next page. The increased number of exemptions required by FDAMA amendments reduced the number of applications that paid fees by well over 30. And this occurred in a year when the total number of applications (non-fee-paying and fee-paying) dropped for the first time in six years as well.

All fees may be waived or reduced under the waiver provisions of the statute. Many of the application fee waiver requests FDA received in the past pertained to orphan products; since designated orphan products are now given automatic exemptions, the number of waiver requests for application fees has decreased substantially.

The tables on the following page summarize the exemption and waiver actions taken by FDA for FY's 1993 through 1996, FY 1997, and FY 1998, and pending waiver requests from the same periods.

EXEMPTIONS AND WAIVERS
(Exemptions counted in Full Application Equivalents)

 

  FY 1993 Through FY 1996 FY 1997 FY 1998
       
Exemptions      
APPLICATIONS      
Exemptions Provided      
Orphan Product
Treated as Waivers Treated as Waivers 16
Pediatric Supplements
Treated as Waivers Treated as Waivers 8
Small Business
13 4.5 15
Total Exemptions 13 4.5 42
       
TOTAL VALUE OF APPLICATION EXEMPTIONS $2,349,000 $923,000 $10,659,109
       
Approved Waivers      
APPLICATIONS      
Waivers Approved 56 9 2
Value of Waivers Approved $8,249,750 $1,486,250 $513,702
       
PRODUCTS:      
Waivers Approved 141 40 18
Value of Waivers Approved $1,477,000 $528,000 $334,638
       
ESTABLISHMENTS:      
Waivers Approved 33 11 10
Value of Waivers Approved $3,623,000 $1,272,700 $1,161,707
       
TOTAL VALUE OF
WAIVERS APPROVED:
$13,349,750 $3,286,950 $2,010,047
       
Pending Waivers      
APPLICATIONS:      
Waivers Pending 2 2 0
Allowance for Pending Waivers $50,000 $205,000 $0
       
PRODUCTS:      
Waivers Pending 39 8 21
Allowance for Pending Waivers $437,600 $105,600 $390,411
       
ESTABLISHMENTS:      
Waivers Pending 25 19 4.5
Allowance for Pending Waivers $2,995,100 $2,198,300 $638,847
       
TOTAL ALLOWANCE FOR PENDING WAIVERS: $3,482,700 $2,508,900 $1,029,258

Next Section: Appendix C: Allowable and Excluded Costs for the Process for the Review of Human Drug Applications